/

COGT

Cogent Biosciences, Inc.Pre-market

29.78−1.22 −3.94%USD

NasdaqGS · as of Oct 12, 16:00 ET · 15m delay

Open

30.81

Prev close

31.00

Day range

29.6431.02

52-week range

13.7843.73

Volume

1.86M0.97×

Mkt cap

5.17B

P/E ttm

—

Fwd P/E

-26.79

EPS ttm

-2.25

Div yield

0.00%

Earnings

Aug 10, 2026

From 52w high

−31.90%

Price Chart

Yahoo Finance · delayed

COGTOct 12, 2026O 30.81H 31.07L 29.63C 29.78−1.22 (−3.94%)Vol 1.86M

SMA 5034.86
SMA 20036.10

1Y change +83.04% since Oct 10, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

COGT Cogent Biosciences, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −3.53%
1 month: −10.87%
3 months: −20.50%
6 months: −18.46%
Year to date: −16.16%
1 year: +83.04%

Valuation & ownership

Market cap: 5.17B
Enterprise value: 4.69B
P/E (ttm): —
Forward P/E: -26.79
PEG ratio: —
Price / book: 10.93
Price / sales (ttm): —
EV / EBITDA: -12.12
EPS (ttm): -2.25
EPS (forward): -1.11
Beta (5y monthly): 0.31
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 173.52M
Float: 172.33M
Short % of float: 11.28%
Short ratio (days): 9.63
Held by insiders: 0.42%
Held by institutions: 115.23%
Avg volume (3m): 1.91M
50-day average: 34.86
200-day average: 36.10
52-week change: +83.04%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): 33.6
vs 50-day SMA: −14.56%
vs 200-day SMA: −17.51%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▲ above
ATR (14) % of price: 4.52%
Realised vol (20d, ann.): 35.5%
From 52-week high: −31.90%
From 52-week low: +116.11%

ANR

Analyst Consensus

11 analysts

Consensus

Strong buy

1.33 on a 1 (strong buy) – 5 (sell) scale

Mean target

55.82

+87.44% implied

Low 45.00Median 55.00High 62.00

Recommendation trend

Now11 / 1 / 0
1m ago / 1 /

DES

About Cogent Biosciences, Inc.

Yahoo Finance profile

Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma; CGT4255, a novel ErbB2 mutant program, which is focused on actionable and underserved mutations in a solid tumor systemic and CNS involved indications; and CGT6297, a Novel PI3Ka mutant-selective inhibitor. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts.

Sector: Healthcare
Industry: Biotechnology
Employees: 258
Headquarters: Waltham, MA, United States
Website: cogentbio.com
Officers: Mr. Andrew R. Robbins M.B.A. President, CEO & Director
Mr. John L. Green C.A., CPA CFO & Principal Accounting Officer

SEAS

Seasonality · COGT

2018–2026 · monthly returns

Strongest month Jul +69.35%Weakest month Sep −11.09%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	1.1	8.2	-0.9	-7.0	-2.3	10.7	0.6	-10.1	-8.5	-7.0			−16.2%
2025	19.4	-19.1	-20.5	-13.0	4.4	32.0	59.1	5.8	18.9	13.5	146.7	-11.7	+355.4%
2024	-24.7	58.0	-4.0	-3.3	23.2	5.2	11.9	13.9	0.6	6.4	-17.2	-18.0	+32.7%
2023	30.3	-12.2	-18.4	-0.3	9.1	0.9	9.7	-6.0	-20.1	-16.3	-6.0	-23.3	−49.1%
2022	-11.9	-21.6	26.3	-14.3	-28.2	95.7	22.9	48.7	-9.5	-8.5	-7.8	-8.1	+34.7%
2021	-21.9	-10.6	12.0	-1.0	-0.3	-6.4	-26.0	38.0	1.6	0.8	-6.6	8.3	−23.6%
2020	1.4	-8.2	-38.4	4.1	30.5	-18.0	484.8	6.3	-18.2	31.6	-20.4	14.5	+289.9%
2019	-1.8	-1.6	3.3	-26.2	-3.7	-16.0	-24.4	-3.0	-25.0	-9.0	-43.8	-2.2	−83.6%
2018				3.1	7.5	16.6	16.9	-2.7	-36.8	-27.4	-7.8	-36.2	−60.4%

INSD

Insider Activity · COGT

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

205.5K shares

Sells, 6 months

45.5K shares

Net shares

+160K

Net change in insider shares

+27.80%

Date	Insider	Transaction	Shares	Value
Aug 26, 2026	Morris Arlene M.Director	Sale at price 37.09 - 37.54 per share.	45.5K	$1.69M
Aug 26, 2026	Morris Arlene M.Director	Conversion of Exercise of derivative security at price 2.52 - 5.64 per share.	45.5K	$245.50K
May 18, 2026	Robbins Andrew R.Chief Executive Officer	Stock Gift at price 0.00 per share.	160K	—
Jan 21, 2026	Fairmount Funds Management LlcDirector	Sale at price 36.40 per share.	3.50M	$127.40M
Dec 25, 2025	Kearns Evan D J.D.Officer	Sale at price 38.70 per share.	65K	$2.52M
Dec 25, 2025	Green John LChief Financial Officer	Sale at price 38.68 per share.	77K	$2.98M
Dec 25, 2025	Sachs Jessica M.D.Officer	Sale at price 38.70 per share.	82.6K	$3.20M
Dec 25, 2025	Robinson John EdwardOfficer	Sale at price 38.74 per share.	90K	$3.49M
Dec 16, 2025	Robbins Andrew R.Chief Executive Officer	Stock Award(Grant) at price 0.00 per share.	1.02M	—
Dec 16, 2025	Kearns Evan D J.D.Officer	Stock Award(Grant) at price 0.00 per share.	300K	—
Dec 16, 2025	Green John LChief Financial Officer	Stock Award(Grant) at price 0.00 per share.	350K	—
Dec 16, 2025	Sachs Jessica M.D.Officer	Stock Award(Grant) at price 0.00 per share.	370K	—
Dec 16, 2025	Robinson John EdwardOfficer	Stock Award(Grant) at price 0.00 per share.	370K	—
Dec 16, 2025	Pinnow ColeOfficer	Stock Award(Grant) at price 0.00 per share.	264K	—
Jul 9, 2025	Fairmount Funds Management LlcDirector	Purchase at price 9.00 per share.	2.78M	$25.00M
Jan 13, 2025	Pinnow ColeOfficer	Purchase at price 7.60 per share.	43.8K	$332.41K

13F

Investors Holding COGT

latest 13F filings of 29 followed managers

Investors holding COGT
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$38.6M	0.05%	996.17K	+41%	Q2 2026
Oaktree Capital · Howard Marks	$14.8M	0.20%	11.89M	+16%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

COGT

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

COGT

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Cogent Biosciences, Inc.

Seasonality · COGT

Insider Activity · COGT

Congress Trades · COGT

Investors Holding COGT

Investors Holding COGT

Congress Trades · COGT

Insider Activity · COGT

Seasonality · COGT

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Cogent Biosciences, Inc.

Financial Snapshot

Earnings & Dividends

News